Asset profile
Pyrotinib
Small molecule
Phase 3underway
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. No registrational readout date is posted for this indication; a Phase 3 is registered in Breast Cancer (NCT04290793); see the registry list.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
62 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 58 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Pyrotinib: this drug | Phase 3 | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Dacomitinib PF-00299804 | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Ceritinib | Approved | Small molecule | ALK |
…and 47 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(46 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (9)
November 2026 (4)
Phase 1/2HER2-expressing Advanced Solid TumorsRecruiting
Est. primary completion 2026-11 · NCT06015048 · CT.gov ↗
What to watch
Phase 1Breast CancerRecruiting
Est. primary completion 2026-11-01 · NCT06770296 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-11-01 · NCT06254690 · CT.gov ↗
What to watch
Early phase / not applicableBreast Cancer FemaleRecruiting
Est. primary completion 2026-11-30 · NCT06035679 · CT.gov ↗
What to watch
December 2026 (5)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT05482568 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04486911 · CT.gov ↗
What to watch
Phase 2/3Breast CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04290793 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT05751018 · CT.gov ↗
What to watch
Phase 2HER2-positive Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT07635342 · CT.gov ↗
What to watch
2027 (16)
February 2027 (2)
Phase 1/2Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Metastatic Breast CancerRecruiting
Est. primary completion 2027-02 · NCT07708194 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-02-26 · NCT06208410 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2HER2-positive Breast CancerNot yet recruiting
Est. primary completion 2027-05-31 · NCT06973525 · CT.gov ↗
What to watch
June 2027 (2)
August 2027 (2)
September 2027 (1)
Phase 2HER2 + Breast CancerRecruiting
Est. primary completion 2027-09-30 · NCT07393425 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Lung Cancer Stage III, MutationRecruiting
Est. primary completion 2027-11-01 · NCT06563999 · CT.gov ↗
What to watch
December 2027 (7)
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT05745740 · CT.gov ↗
What to watch
Early phase / not applicableHER2-positive Breast CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT06718335 · CT.gov ↗
What to watch
Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT07014410 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07653451 · CT.gov ↗
What to watch
2028 (14)
January 2028 (1)
Phase 2HER2-positive Breast Cancer, Neoadjuvant Therapy, PyrotinibRecruiting
Est. primary completion 2028-01 · NCT06832904 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2028-05-06 · NCT05841381 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Breast Cancer Early Stage Breast Cancer (Stage 1-3)Recruiting
Est. primary completion 2028-06-30 · NCT07797218 · CT.gov ↗
What to watch
July 2028 (2)
August 2028 (1)
Phase 2Metastatic Breast Cancer With HER2 PositiveNot yet recruiting
Est. primary completion 2028-08-30 · NCT07132242 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Advanced Breast CancerRecruiting
Est. primary completion 2028-09 · NCT07180082 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-10-30 · NCT07836257 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast CancerRecruiting
Est. primary completion 2028-11-01 · NCT07610720 · CT.gov ↗
What to watch
December 2028 (5)
Phase 3Breast CancerRecruiting
Est. primary completion 2028-12-14 · NCT04646759 · CT.gov ↗
What to watch
Phase 2Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-30 · NCT05769010 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2028-12-30 · NCT07615751 · CT.gov ↗
What to watch
Phase 1/2Advanced/ Metastatic Her-2 Positive Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT05575804 · CT.gov ↗
What to watch
Phase 2HER2-positive Early Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT07340398 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
Phase 2Breast Cancer, HER2-positive Breast CancerNot yet recruiting
Est. primary completion 2029-01-31 · NCT07417241 · CT.gov ↗
What to watch
2030 (3)
April 2030 (1)
Phase 3Breast Cancer InvasiveRecruiting
Est. primary completion 2030-04 · NCT05910398 · CT.gov ↗
What to watch
2031 (3)
June 2031 (1)
Phase 3HER2-positive Metastatic Breast Cancer, First-line TreatmentRecruiting
Est. primary completion 2031-06-30 · NCT06278870 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.